



PRESS RELEASE

Uppsala July 12, 2010

Q-Med AB invites to Q2 conference call

Q-Med's half-year report for the period January-June 2010 will be published on Thursday July 22 at approximately 10:30 CET.

Media and analysts are invited to participate in a press conference at which the report will be presented by Bengt Ågerup, President and CEO and Alexander Kotsinas, CFO.

Time: Thursday July 22 at 11:30 a.m. CET.

Conference id: 87 04 10

To join the conference call dial: Sweden +46 8 505 201 14 or UK +44 (0)207 1620 177.

The slide presentation will be available at www.q-med.com and Investors/Presentations.

A recorded version of the presentation will be available for seven working days on tel: Sweden +46 8 505 203 33 or UK +44 (0)207 0314 064, access code 87 04 10.

Financial information 2010

October 22 - Interim Report January – September 2010

Queries should be addressed to:

Kristin Ermanbriks, IR Co-ordinator

Tel: +46 70 974 90 71

*Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, **NASHA**[™], for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane**[®] for filling lines and folds, contouring and creating volume in the face, **Macrolane**[™] for body contouring, **Durolane**[™] for the treatment of osteoarthritis of the hip and knee joints, **Deflux**[®] for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta**[®] for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.*
